Author: jezzabellemente

“Eyhey (hey), Ma (you), Hamo (OK)”… Drawing attention with additive rhythm beyond its sincerity

BUSAN, South Korea, Feb 25 (Bernama-BUSINESS WIRE) — The Busan Metropolitan City and Busan Tourism Organization (BTO) released a promotional video produced to introduce the unique vibe of Busan, an international tourism city, to the global market through Visit Busan YouTube channel on February 10.

This promotional video was planned as a unique content of Busan under the three themes of Sanbokdoro (Sanbok Road), Busan Eomuk (fish cake), and the vibe of Busan. The video shows the thrilling bus drive that can only be experienced on Sanbokdoro, Busan’s signature food, Eomuk and warm atmosphere in a traditional market, and the vibe of Busan spread in Sajik Baseball Stadium, the world’s largest Karaoke.

In particular, Eyheymahamo, a catchphrase similar to Abracadabra or Hakuna Matata that is repeated throughout the video, arouses the curiosity of overseas viewers. Eyheymahamo is a compound word of Eyhey, Ma, and Hamo, the dialect of Busan. This phrase means, “Hey, don’t worry. You’re okay.”

Mudd the Student, a rapper from Busan who competed at ‘Show Me the Money Season 10’ composed the song using the dialect of Busan and appeared on the video. The video also features choreography created by Hook, a dance crew from Street Woman Fighter. These artists will continue performing as the publicity models for Busan tourism.

Following the release of the video, the Busan Metropolitan City and BTO will start publicizing it from February 25 in the form of a short-form challenge together with famous global influencers using Tiktok, a global short video platform, and Weibo, a Chinese microblogging website.

With the video that shows the charm of Busan, an international tourism city, the Busan Metropolitan City will increase the global recognition of Busan as a city most loved by Koreans and a city overseas tourists would want to visit.

Visit the Visit Busan YouTube channel to watch the video: https://www.youtube.com/c/VISITBUSAN

Photos/Multimedia Gallery Available:
https://www.businesswire.com/news/home/52582830/en

Contact

Busan Tourism Organization
Strategic Planning Team
Mangil Cho, +82-51-780-2127
jomangil@bto.or.kr

Source : Busan Tourism Organization

http://mrem.bernama.com/viewsm.php?idm=42494

Global CDMO’s Heidelberg Facility Supplies more pDNA material to help address growing needs

Heidelberg, Germany, Feb 9 (Bernama-GLOBE NEWSWIRE) —AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.

According to a recent news release from Pfizer and BioNTech, the companies have started to develop an Omicron-based COVID-19 vaccine with first batches expected to be ready for delivery by end of March 2022.

“We are proud to continue to support BioNTech and supply them with pDNA materials for their vaccine production, as a part of the fight against new pandemic variants,” said AGC Biologics Chief Executive Officer, Patricio Massera. “Our pDNA services are a part of our growing global Cell and Gene Therapy offering that includes the development and manufacturing of cell therapies, viral vectors, and messenger RNA.”

“This type of work is what drives us every day,” says AGC Biologics General Manager, Heidelberg, Dieter Kramer. “We appreciate this opportunity to help make a difference in the lives of people around the world and produce life-saving treatments.”

The AGC Biologics Heidelberg facility has more than 20 years of experience delivering a wide range of programs for customers. The site is the company’s Center of Excellence for pDNA production, and a central part of the AGC Biologics global network of cell and gene therapy-focused facilities, with additional locations in Milan, Italy and Longmont, Colorado, USA.

For more information on AGC Biologics’ Plasmid DNA offering visit www.agcbio.com/plasmid-dna. To learn more about the company’s broader cell and gene therapy services visit www.agcbio.com/cell-therapy.

About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

Nick McDonald
AGC Biologics
(425) 419-3555
nmcdonald@agc.com

Source: AGC Biologics

–BERNAMA

Prestigious Sunhak Peace Prize Laureates to be Honored

Washington, DC, Feb 8 (Bernama-GLOBE NEWSWIRE) —FOR IMMEDIATE RELEASE

Global Summit Gathers World Leaders on

Peaceful Reconciliation of the Korean Peninsula

Prestigious Sunhak Peace Prize Laureates to be Honored

The upcoming World Summit 2022 (Summit for Peace on the Korean Peninsula) will gather world leaders and a worldwide virtual audience around topics related to peaceful reconciliation on the Korean Peninsula.

The Feb. 10-13 World Summit 2022, held in Seoul, South Korea, is sponsored by the Universal Peace Federation (UPF) and the Kingdom of Cambodia. It will feature keynote speakers from around the world on a range of topics related to the peaceful reconciliation of the Korean Peninsula. Many speakers are from the 157 countries that have diplomatic ties with both North and South Korea.

World Summit 2022 is hosted by UPF Co-Founder Dr. Hak Ja Han Moon, and co-chaired by Samdech Hun Sen, Prime Minister of the Kingdom of Cambodia, and H.E. Ban Ki-moon, former United Nations Secretary-General (2007-2016).

A highlight of the Summit is the 5th Sunhak Peace Prize Award Ceremony, to be held on Feb. 12, which will honor Oxford University vaccinologist Prof. Sarah Gilbert and Gavi, the Vaccine Alliance for their efforts to serve humanity during the COVID-19 pandemic.

H.E. Hun Sen will be honored with the 2nd Sunhak Peace Prize Founder’s Award, which is given to recognize distinguished world leaders who demonstrate significant accomplishments for peace throughout their careers.

The Sunhak Peace Prize, founded in 2013 by Dr. Moon to honor the legacy of her late husband Rev. Dr. Sun Myung Moon, is intended to “find and scale up the best peace solutions we can find,” organizers said at a Feb. 7 press conference to announce the 2022 Laureates. Speakers included H.E. Chring Botum Rangsay, Cambodian Ambassador to South Korea; H.E. Jose Manuel Barroso, chairman of the Sunhak Peace Prize; and Sunhak Peace Prize leaders, Washington Times Chairman Thomas P. McDevitt, Dr. Nam In-seog and Dr. Yun Young-ho. Laureates receive a cash prize, medal and plaque.

Adhering to South Korea’s COVID-19 safety guidelines, distinguished participants from around the world will gather in Seoul for World Summit 2022, which begins with the Opening Plenary at the Republic of Korea National Assembly on Friday, Feb. 11, 2022 (KST). Millions more will participate in the Summit via a high-tech hybrid format.

“The Korean War began more than 70 years ago and concluded with an armistice, not a peace treaty,” said UPF Chairman Dr. Thomas G. Walsh. “The Korean Peninsula is populated by a people with thousands of years of common history, culture and language. Is it not possible to resolve this conflict and bring about the peaceful reunification of the peninsula? We will seek answers to these questions at the Summit,” Dr. Walsh said.

In addition to the 5th Sunhak Peace Prize Award Ceremony, World Summit 2022 will hold the Global Assembly of Heads of State and Government, the Interreligious Peace Summit and the Rally for Peace on the Korean Peninsula that will involve more than one million people.

Moreover, before and during World Summit 2022, organizers will convene high-level sessions around the work of UPF’s peacebuilding associations. These include:

· International Summit Council for Peace (ISCP) and the International Association of First Ladies for Peace (IAFLP)
· International Association of Parliamentarians for Peace (IAPP)
· Interreligious Association for Peace and Development (IAPD)
· International Association for Peace and Economic Development (IAED)
· International Media Association for Peace (IMAP)
· International Association of Academicians for Peace (IAAP)
· International Association of Arts and Culture for Peace (IAACP)

World Summit 2022 is part of UPF’s ongoing series of peacebuilding activities, which are held under the theme of mutual prosperity, interdependence and shared universal values.

UPF, an NGO in General Consultative Status with the Economic and Social Council of the United Nations, is known for its Rally of Hope series, the International Leadership Conference series, and, since early 2021, the Forum series of Think Tank 2022. The latter project was created to engage more than 2,000 global thought leaders on how to achieve a breakthrough for peace on the Korean Peninsula. (Details about Think Tank 2022 Forums can be found at UPF.org)

For media inquiries, please contact:

William P. Selig | Communications Director, Universal Peace Federation

Ph: 240-274-1744 | Email: wselig@upf.org | Web: www.upf.org

Attachment

· UPF WS2022

William P. Selig
Universal Peace Federation
240-274-1744
wselig@upf.org

Source: Universal Peace Federation USA

–BERNAMA

NEW YORK, Feb 7 (Bernama-BUSINESS WIRE) — Medidata, a Dassault Systèmes company, announced today that Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, is extending their 15-year global strategic partnership. This builds upon the trusted relationship between the two companies and sets the goal of jointly pioneering a new era of decentralized clinical trial technology (DCT) for the life sciences industry.

“Parexel’s priority focus is on providing patient-centered solutions that enhance the clinical trial experience and make participation more accessible to everyone,” said Clare Grace, Ph.D., Chief Patient Officer at Parexel. “Medidata’s DCT technologies further support our efforts in a market where nearly 75% of proposals include at least a hybrid trial model. We’re pleased to partner with them as we continue to expand our offerings in this area.”

Anthony Costello, Patient Cloud CEO at Medidata, added: “The COVID-19 pandemic showed us that we can leverage DCT technologies to expedite and enhance the entire clinical trials process. The relationship with Parexel represents an enormous opportunity to forever redefine the patient experience and development timelines for the development of new medicines and vaccines.”

Parexel also participates in Medidata’s Early Adopter DCT program leveraging its unified platform, the myMedidata patient portal, Sensor Cloud, and Medidata’s proprietary Patient Centricity by Design program. Parexel provides feedback and insights to help ensure the portal meets the needs of patients, sites, and sponsors. With myMedidata, patients can virtually access all of their clinical trial needs through one web-based portal, removing the need for provisioned devices and improving clinical trial experiences.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,900+ customers and partners access the world’s most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 290,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20220204005074/en/

Contact

Tom Paolella
Senior Director, Corporate Communications & Affairs
+1-848-203-7596
thomas.paolella@3ds.com

Paul Oestreicher
External Communications Director
+1-917-522-4692
paul.oestreicher@3ds.com

Source : Medidata

–BERNAMA

KUALA LUMPUR, Feb 3 — On World Wetland Day, Mary Kay Inc, a global leader in corporate sustainability and eco-responsibility, has made a renewed commitment with The Nature Conservancy to preserve the precious wetlands that line—and protect—our coasts.

According to a statement, Mary Kay’s partnership with The Nature Conservancy (TNC) began in 1990.

In the decades since then, they’ve combined forces to engage Indigenous peoples in sustainable aquaculture in New Zealand, secure fresh water for people in Mexico, clean up oceans, and save species and empower women in the Solomon Islands.

Their latest project with TNC, which kicked off in 2019, focused on the preservation and enhancement of wetlands.

“Coastal wetlands provide the trifecta of climate wins: carbon capture, adaptation to sea-level rise, and increased resiliency to storms and flooding, all while supporting local and national economies,” said Chief Operating Officer at Mary Kay Inc, Deborah Gibbins.

“Unfortunately, Texas—Mary Kay’s home state—has lost more than half of its coastal wetlands in the past 200 years to habitat conversion, overgrazing and development. On World Wetlands Day, Mary Kay is recommitting its efforts to protecting our wetlands to benefit generations to come.”

Meanwhile, Texas Resilient Coast Program Director at The Nature Conservancy, Lauren Williams said: “Through our partnership with Mary Kay, we’re committed to supporting growth along the coast that is sustainable for the economy, the environment, and the wildlife species that depend on it.”

Together, Mary Kay and TNC will work toward the objectives to protect wetlands over the next year including identify priority wetland areas for protection and restoration across more than 27,000 kilometres of shoreline along the Gulf of Mexico.

This also include Assess the feasibility of blue carbon markets to support long-term wetland management needs in Texas; and, Identify a dynamic coastal wetland site that can be established as a ‘living laboratory’ to share conservation techniques, explore blue carbon offsets and highlight the importance of these critical ecosystems.

— BERNAMA